ARID1A and colorectal carcinoma: Our results not only indicate that ARID1A could be potentially used, if further confirmed, as a predictive biomarker for excluding patients from cetuximab treatment but also provide a rationale for exploring therapeutic MAPK inhibition in a previously unsuspected genetically defined segment of CRC patients.